sofosbuvir and daclatasvir - versus placebo - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 1.13 [0.89, 1.43]< 10%2 studies (2/-)16.2 %lownot evaluable highcrucial-
deaths 1.15 [0.90, 1.47]< 10%2 studies (2/-)12.6 %lownot evaluable highcrucial-
hospital discharge 1.01 [0.95, 1.08]> 10%1 study (1/-)61.9 %NAnot evaluable important-
mechanical ventilation 1.52 [0.72, 3.19]< 10%1 study (1/-)13.4 %NAnot evaluable important-
recovery 0.97 [0.89, 1.05]> 10%1 study (1/-)23.5 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.